Prospect Venture Partners, L.P.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

Nora Therapeutics, Inc. is a biotechnology company based in Palo Alto, California, specializing in therapeutics aimed at addressing unmet needs in reproductive medicine. The company’s lead product, NT100, is a biologic agent designed to enhance pregnancy success rates for women who have experienced multiple unsuccessful in vitro fertilization (IVF) attempts or recurrent miscarriages. NT100 mimics a naturally occurring protein found in the female reproductive tract and works by optimizing maternal-fetal immune tolerance, thereby improving the chances of embryo implantation and pregnancy maintenance. Founded in 1992, Nora Therapeutics is dedicated to providing innovative solutions for women facing challenges in reproductive health.

Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.

NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, provides real-time volumetric images of the esophagus and bile duct, enabling healthcare professionals across various specialties, including gastroenterology and pulmonology, to conduct advanced imaging procedures. This technology allows for high-resolution, cross-sectional views that facilitate accurate diagnoses and effective therapies during medical procedures. NinePoint aims to enhance the efficiency of patient care by integrating access to imaging, diagnosis, and treatment in a single procedure, ultimately improving patient outcomes and reducing healthcare costs. The company markets its products through distributors both domestically and internationally. Established in 2008, NinePoint Medical was formerly known as Convergence Devices, Inc. and underwent a name change in 2009.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

TOPICA Pharmaceuticals, Inc. is a clinical research stage pharmaceutical company dedicated to developing luliconazole for the treatment of onychomycosis, a fungal infection affecting the nails. With over 35 million Americans estimated to suffer from this condition and limited treatment options available, TOPICA aims to provide an effective solution. Luliconazole is notable for its potent antifungal activity, excellent safety profile, and ability to quickly penetrate the nail plate to reach the infection site in the nail bed. Following a successful Phase 1/2a clinical trial in 2011, which demonstrated the drug's efficacy and tolerability, the company is now focused on conducting further studies to establish optimal dosing and proof of efficacy. The goal is to position luliconazole as a leading topical therapy for onychomycosis, potentially transforming the treatment landscape for this prevalent condition.

Azelon Pharmaceuticals, formerly Zelos Therapeutics, a West Conshohocken, PA-based company focused on the development of novel formulations for the treatment of osteoporosis.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

SurePoint Medical, LLC is a Lawrence, Kansas-based company that specializes in providing mail-order diabetes supplies across the United States. The company focuses on delivering essential products to individuals managing diabetes, ensuring they have convenient access to the supplies they need for effective self-care. With a commitment to customer service and efficient delivery, SurePoint Medical aims to improve the quality of life for those living with diabetes by streamlining the process of obtaining necessary medical supplies.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, provides real-time volumetric images of the esophagus and bile duct, enabling healthcare professionals across various specialties, including gastroenterology and pulmonology, to conduct advanced imaging procedures. This technology allows for high-resolution, cross-sectional views that facilitate accurate diagnoses and effective therapies during medical procedures. NinePoint aims to enhance the efficiency of patient care by integrating access to imaging, diagnosis, and treatment in a single procedure, ultimately improving patient outcomes and reducing healthcare costs. The company markets its products through distributors both domestically and internationally. Established in 2008, NinePoint Medical was formerly known as Convergence Devices, Inc. and underwent a name change in 2009.

Pathwork Diagnostics, located in Redwood City, California, specializes in developing and delivering innovative molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers, by utilizing genomic information from the tumors. Pathwork Diagnostics offers laboratory services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen tissues, providing essential support in cancer diagnosis and treatment planning.

Complete Genomics specializes in high-quality, affordable DNA sequencing and analysis, facilitating large-scale research into the genetic mechanisms of drug responses and complex diseases. The company has developed a comprehensive genomics analysis platform that integrates proprietary human sequencing technology with advanced informatics and data management software. This approach ensures that customers receive ready-to-use data for genome-based research, supporting advancements in personalized medicine and broader genetic studies. By combining innovative technology with a unique market strategy, Complete Genomics aims to transform the landscape of DNA sequencing.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company utilizes its proprietary platform technology, Pro/PEG, which is a bioadhesive polymer hydrogel. Neomend specializes in a combination wound sealant and adhesion barrier product designed for use during minimally invasive or laparoscopic surgical procedures, aiming to enhance patient outcomes and improve recovery times.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for autoimmune and gastrointestinal diseases, with a particular emphasis on celiac disease. The company's lead product candidate, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is working on proteases that target other aspects of celiac disease, including Transglutaminase 2 (TG2) and the HLA-DQ2 antigen. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC as of February 2016.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

Complete Genomics specializes in high-quality, affordable DNA sequencing and analysis, facilitating large-scale research into the genetic mechanisms of drug responses and complex diseases. The company has developed a comprehensive genomics analysis platform that integrates proprietary human sequencing technology with advanced informatics and data management software. This approach ensures that customers receive ready-to-use data for genome-based research, supporting advancements in personalized medicine and broader genetic studies. By combining innovative technology with a unique market strategy, Complete Genomics aims to transform the landscape of DNA sequencing.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics aimed at addressing significant medical conditions with unmet needs. The company is primarily engaged in in-licensing and marketing late-stage product candidates within the central nervous system therapeutic area. Somaxon is known for promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia, which is currently available in the United States. In addition to sleep disorders, Somaxon has also developed products for the treatment of other conditions, including middle ear infections, head lice, and cough and cold.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Visiogen, Inc. is an ophthalmic medical device company focused on developing innovative vision solutions for patients with cataracts, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless range of near, intermediate, and distance vision without the need for glasses or contact lenses. This advanced device is supplied in a pre-loaded injector to minimize lens handling during surgical procedures. Visiogen's technology has received CE Mark approval in Europe and is currently in clinical trials in the United States, aiming to enhance the quality of life for cataract patients through improved vision correction options.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

SurgRx is a developer of laparoscopic vessel fusion tools for surgical hemostasis.

Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company utilizes its proprietary platform technology, Pro/PEG, which is a bioadhesive polymer hydrogel. Neomend specializes in a combination wound sealant and adhesion barrier product designed for use during minimally invasive or laparoscopic surgical procedures, aiming to enhance patient outcomes and improve recovery times.

Roxro Pharma, Inc. is a biopharmaceutical company focused on developing innovative drugs for pain management. Founded in 1999 and based in Menlo Park, California, the company specializes in intranasal formulations aimed at addressing various types of pain. Its primary products include ROX-888, designed for the treatment of dental and postoperative pain, and ROX-828, a non-opioid and non-triptan formulation targeted at migraine relief. Through its research and development efforts, Roxro Pharma aims to provide effective alternatives for individuals suffering from pain.

SurgRx is a developer of laparoscopic vessel fusion tools for surgical hemostasis.

Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

Aspen Medtech, a Bellevue, WA-based medical device incubator.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs targeting inflammatory diseases. The company's research team leverages deep insights into bioactive lipid pathways and complex signaling mechanisms that influence various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular issues, and fibrotic diseases. Through its focused approach, Amira aims to develop effective treatments that address unmet medical needs in the realm of inflammation-related health challenges.

Visiogen, Inc. is an ophthalmic medical device company focused on developing innovative vision solutions for patients with cataracts, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless range of near, intermediate, and distance vision without the need for glasses or contact lenses. This advanced device is supplied in a pre-loaded injector to minimize lens handling during surgical procedures. Visiogen's technology has received CE Mark approval in Europe and is currently in clinical trials in the United States, aiming to enhance the quality of life for cataract patients through improved vision correction options.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs targeting inflammatory diseases. The company's research team leverages deep insights into bioactive lipid pathways and complex signaling mechanisms that influence various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular issues, and fibrotic diseases. Through its focused approach, Amira aims to develop effective treatments that address unmet medical needs in the realm of inflammation-related health challenges.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for autoimmune and gastrointestinal diseases, with a particular emphasis on celiac disease. The company's lead product candidate, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is working on proteases that target other aspects of celiac disease, including Transglutaminase 2 (TG2) and the HLA-DQ2 antigen. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC as of February 2016.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Pathwork Diagnostics, located in Redwood City, California, specializes in developing and delivering innovative molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers, by utilizing genomic information from the tumors. Pathwork Diagnostics offers laboratory services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen tissues, providing essential support in cancer diagnosis and treatment planning.

Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Hansen Medical, Inc. specializes in the development, manufacture, and sale of medical robotics aimed at enhancing the positioning, manipulation, and control of catheters and catheter-based technologies. The company offers the Sensei systems and Artisan Control Catheters, which are used in electrophysiology procedures to improve catheter navigation and control. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that enhances physicians' ability to visualize catheter placement in three dimensions. Another key product is the Magellan Robotic System, which facilitates remote navigation and vessel cannulation using a telescoping, robotically steerable catheter. The company markets and supports its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and headquartered in Mountain View, California, Hansen Medical operates as a subsidiary of Auris Surgical Robotics, Inc. since July 2016.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Roxro Pharma, Inc. is a biopharmaceutical company focused on developing innovative drugs for pain management. Founded in 1999 and based in Menlo Park, California, the company specializes in intranasal formulations aimed at addressing various types of pain. Its primary products include ROX-888, designed for the treatment of dental and postoperative pain, and ROX-828, a non-opioid and non-triptan formulation targeted at migraine relief. Through its research and development efforts, Roxro Pharma aims to provide effective alternatives for individuals suffering from pain.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs targeting inflammatory diseases. The company's research team leverages deep insights into bioactive lipid pathways and complex signaling mechanisms that influence various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular issues, and fibrotic diseases. Through its focused approach, Amira aims to develop effective treatments that address unmet medical needs in the realm of inflammation-related health challenges.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics aimed at addressing significant medical conditions with unmet needs. The company is primarily engaged in in-licensing and marketing late-stage product candidates within the central nervous system therapeutic area. Somaxon is known for promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia, which is currently available in the United States. In addition to sleep disorders, Somaxon has also developed products for the treatment of other conditions, including middle ear infections, head lice, and cough and cold.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of therapies aimed at addressing significant unmet medical needs, particularly in central nervous system disorders. The company's marketed products include HETLIOZ, which treats non-24-hour sleep-wake disorders and sleep disturbances associated with Smith-Magenis Syndrome, and Fanapt, used for schizophrenia. Vanda's pipeline features several investigational therapies, including HETLIOZ for jet lag disorder and pediatric non-24, Tradipitant for atopic dermatitis and motion sickness, and VTR-297, a histone deacetylase inhibitor targeting hematologic malignancies. Additionally, the company is exploring treatments for various psychiatric disorders and conditions related to cystic fibrosis. Vanda Pharmaceuticals primarily markets its products in the United States, Europe, and Israel and is headquartered in Washington, D.C.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

SurgRx is a developer of laparoscopic vessel fusion tools for surgical hemostasis.

Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.

Rejuvenon a biopharmaceutical company committed developing and commercializing promising compounds for treatment of oncologic diseases.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

Jazz Pharmaceuticals is a biopharmaceutical company based in Ireland that specializes in developing and commercializing innovative treatments for neurology and oncology, particularly in underserved markets. The company has nine approved drugs, including Xyrem and Xywav, which treat narcolepsy, and Zepzelca, Rylaze, and Vyxeos, aimed at various cancers such as metastatic small cell lung cancer and acute leukemias. Additionally, Jazz acquired GW Pharmaceuticals, enhancing its portfolio with Epidiolex, a treatment for severe, rare forms of epilepsy. Other notable products include Cystadane for homocystinuria and Antizol for ethylene glycol and methanol poisoning. Jazz Pharmaceuticals is committed to addressing significant medical needs through its targeted therapies.

Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Rinat Neuroscience, founded in 2001 following a spin-out from Genentech, focuses on developing protein-based therapeutics for various neurological diseases and disorders. The company leverages significant research and development resources previously invested by Genentech to advance its pioneering efforts in antibody drug development. Rinat is dedicated to creating innovative treatments for conditions such as pain, Alzheimer's disease, obesity, diabetes, and neuropathies. Additionally, it is engaged in developing novel therapies aimed at modifying disease progression by targeting and protecting specific populations of neurons affected by these diseases. Through its work, Rinat Neuroscience seeks to improve patient outcomes in the field of neurology.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

Opus Medical designs and manufactures tissue-to-bone and tissue-to tissue repair systems.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Biospect, Inc. is a life sciences technology company based in South San Francisco, California, focused on developing minimally invasive methods for identifying and analyzing protein biomarker patterns that indicate and differentiate various biological states. The company's integrated system combines proprietary technologies for separations, detection, and informatics, facilitating applications in disease diagnosis, management, and drug development. Biospect's innovations aim to assist medical researchers in their efforts to improve health outcomes and enhance the efficiency of therapeutic interventions. The company is supported by notable investors, including Advent Venture Partners, Prospect Venture Partners, Venrock Associates, and Versant Ventures.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

Infinity Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative treatments for various cancers. The company's lead candidate, eganelisib, is an oral immuno-oncology therapy that aims to reprogram macrophages to counteract immune suppression in cancer. Infinity is conducting multiple clinical trials to evaluate eganelisib in combination with established therapies, including global studies such as MARIO-275, which tests eganelisib alongside Opdivo® in patients with urothelial cancer, and MARIO-3, which explores combinations with Tecentriq® and Abraxane® in triple-negative breast cancer as well as with Tecentriq and Avastin® in renal cell carcinoma. Additionally, Infinity is collaborating with Arcus Biosciences to test a novel regimen that combines eganelisib with etrumadenant and Doxil® for advanced triple-negative breast cancer patients. The company's research also encompasses treatments for hematologic malignancies and solid tumors, reflecting its commitment to addressing various oncological challenges.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.

Metreo is a provider of profit optimization software aimed at improving margins for Global 2000 manufacturers, distributors, and service providers. The company's innovative solution integrates price planning and execution, allowing businesses to set appropriate price targets, assess customer sales requests, recommend profitable responses, and negotiate favorable deals. By simplifying and adding discipline to the pricing process, Metreo helps its clients maximize profits from their goods and services. The company is headquartered in Palo Alto, California.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.